210491-38-6

Upstream product

• 24821-22-5 2,6-bis(trifluoromethyl)benzoic acid 
• 402-31-3 1,3-bis(trifluoromethyl)benzene 
• 124-41-4 sodium methylate 
• 210491-39-7 4-Bromo-2,6-bis-trifluoromethyl-benzoyl fluoride 

Downstream Products

• 890839-32-4 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,6-bis(trifluoromethyl)benzoic acid 
• 1416560-77-4 C₂₅H₂₈F₆N₄O₃S 
• 1416560-76-3 C₂₀H₂₂F₆N₂O₃ 
• 1416560-75-2 C₁₉H₂₂F₆N₂O₄ 
• 1416560-74-1 C₁₉H₂₄F₆N₂O₄ 
• 1416560-73-0 C₁₉H₂₀F₆N₂O₄ 
• 1416560-72-9 C₁₆H₁₇BrF₆N₂O₃ 
• 1263409-66-0 methyl 4-bromo-2,6-bis(trifluoromethyl)benzoate 
• 210491-45-5 (4-Methoxy-3-methyl-2,6-bis-trifluoromethyl-phenyl)-methanol 
• 210491-46-6 4-Methoxy-2,6-bis-trifluoromethyl-benzoyl fluoride 
• 210491-41-1 4-Methoxy-2,6-bis-trifluoromethyl-benzoic acid 
• 210491-47-7 (4-Methoxy-2,6-bis-trifluoromethyl-phenyl)-methanol 
• 210491-39-7 4-Bromo-2,6-bis-trifluoromethyl-benzoyl fluoride 

Relevant academic research and scientific papers

Hexaphyrin as a Potential Theranostic Dye for Photothermal Therapy and 19F Magnetic Resonance Imaging

Two features of meso-Aryl-substituted expanded porphyrins suggest suitability as theranostic agents. They have excellent absorption in near infrared (NIR) region, and they offer the possibility of introduction of multiple fluorine atoms at structurally equivalent positions. Here, hexaphyrin (hexa) was synthesized from 2,6-bis(trifluoromethyl)-4-formyl benzoate and pyrrole and evaluated as a novel expanded porphyrin with the above features. Under NIR illumination hexa showed intense photothermal and weak photodynamic effects, which were most likely due to its low excited states, close to singlet oxygen. The sustained photothermal effect caused ablation of cancer cells more effectively than the photodynamic effect of indocyanine green (a clinical dye). In addition, hexa showed potential for use in the visualization of tumors by 19F magnetic resonance imaging (MRI), because of the multiple fluorine atoms. Our results strongly support the utility of expanded porphyrins as theranostic agents in both photothermal therapy and 19F MRI.

1H-PYRROLO[2,3-B]PYRIDINES

Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.

A site selective functionalisation of 1,3-bis(trifluoromethyl)benzene

1,3-Bis(trifluoromethyl)benzene was regioselectively metalated and subsequently carboxylated at position 2 to give 2,6- bis(trifluoromethyl)benzoic acid. Treatment of the acid with sulphur tetrafluoride gave 2,6-bis(trifluoromethyl)benzoyl fluoride which was readily convened to 2,6-bis(trifluoromethyl)benzyl alcohol and further to 2,6- bis(trifluoromethyl)benzaldehyde. Bromination of 2,6- bis(trifluoromethyl)benzoic acid with 1,1-dibromo-5,5-dimethylhydantoin proceeded regioselectively affording 4-bromo-2,6-bis(trifluoromethyl)benzoic acid almost quantitatively. The latter was fluorinated to the corresponding acid fluoride which on treatment with methanolic sodium methoxide gave 4- methoxy-2,6-bis(trifluoromethyl)benzoic acid or its methyl ester, depending on the reaction conditions. 4-Methoxy-2,6-bis(trifluoromethyl)benzoic acid, via its acid fluoride, was also transformed, first to the corresponding benzyl alcohol, then to the benzaldehyde. Lithiation of 4-methoxy-2,6- bis(triflouromethyl)benzoic acid, followed by methylation, proceeded with low selectivity, nevertheless, methyl 4-methoxy-3-methyl-2,6- bis(trifluoromethyl)benzoate was formed as the main product which was stepwise converted to 4-methoxy-3-methyl-2,6-bis(trifluoromethyl)benzyl alcohol and 4-methoxy-3-methyl-2,6-bis(trifluoromethyl) benzaldehyde, albeit in low total yield.